bringing novel prescription medicines
to the global market for treatment of rare
intestinal failure disorders

Along with our European affiliate, Napo Therapeutics S.p.A., we are focused on the development
program of our novel powder for oral solution formulation of crofelemer for treatment of rare
intestinal failure indications, including pediatric microvillus inclusion disease (MVID) and adult
short bowel syndrome with intestinal failure (SBS-IF).

We are also supporting investigator-initiated proof-of-concept trials of crofelemer in pediatric
MVID and SBS-IF patients, and in adult
SBS-IF patients.

We are conducting a pivotal trial in pediatric MVID patients in the US, EU and UAE
and conducting a Phase 2 trial in adult SBS-IF patients in the EU.

Crofelemer is responsibly harvested from plants located in rainforest regions and works by a
novel mechanism of action: the inhibitory modulation of two secretory chloride ion channels in
the gastrointestinal tract.

bringing novel prescription
medicines to the global
market for treatment of rare
intestinal failure disorders

Along with our European affiliate, Napo
Therapeutics S.p.A., we are focused on
the development program of our novel
powder for oral solution formulation of
crofelemer for treatment of rare intestinal
failure indications, including pediatric microvillus
inclusion disease (MVID) and adult
short bowel syndrome with intestinal failure (SBS-IF).

We are also supporting investigator-initiated
proof-of-concept trials of crofelemer in pediatric
MVID and SBS-IF patients, and in adult SBS-IF patients.

We are conducting a pivotal trial in pediatric
MVID patients in the US, EU and UAE and
conducting a Phase 2 trial in adult SBS-IF
patients in the EU.

Crofelemer is responsibly harvested from
plants located in rainforest regions and
works by a novel mechanism of action:
the inhibitory modulation of two secretory
chloride ion channels
in the gastrointestinal tract.

bringing novel prescription medicines
to the global market for treatment of rare
intestinal failure disorders

Along with our European affiliate, Napo Therapeutics S.p.A., we are focused on the development
program of our novel powder for oral solution formulation of crofelemer for treatment of rare
intestinal failure indications, including pediatric microvillus inclusion disease (MVID) and adult
short bowel syndrome with intestinal failure (SBS-IF).

We are also supporting investigator-initiated proof-of-concept trials of crofelemer in pediatric
MVID and SBS-IF patients, and in adult
SBS-IF patients.

We are conducting a pivotal trial in pediatric MVID patients in the US, EU and UAE
and conducting a Phase 2 trial in adult SBS-IF patients in the EU.

Crofelemer is responsibly harvested from plants located in rainforest regions and works by a
novel mechanism of action: the inhibitory modulation of two secretory chloride ion channels in
the gastrointestinal tract.

uncovering medical solutions to serve those in need

We have investigated the ability of our product to provide relief to those in need across multiple indications. Our diverse pipeline and clinical trials span various stages of research.

connecting motivated minds

We strive to advance the understanding and potential of our products by supporting high-quality research initiated and executed by external investigators.

sustaining our natural resources

We prioritize environmental sustainability as well as social responsibility, harvesting our product responsibly and sharing benefits with the local communities that make our mission possible.

our commitment